Cutler Group’s Forte Biosciences FBRX Stock Holding History

Cutler Group’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,208	Closed	-$4K	–	5566
2021 Q3	$4K	Buy	+1,208	New	+$669K	﹤0.01%	4593

Other funds holding FBRX

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cutler Group's FBRX Position: Q1 2024 in Review

Cutler Group sold out of Forte Biosciences (FBRX) in Q1 2024, closing a stake of 159 shares — an estimated $3K sold.

Cutler Group first reported a position in FBRX in Q3 2021 and held it in 10 quarters. The position peaked at $47K in Q3 2021. 32 funds tracked by Wall St. Rank hold FBRX as of Q1 2024.

Cutler Group reported no remaining Forte Biosciences position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 159 Forte Biosciences shares in Q1 2024, an estimated $3K.
Cutler Group first reported a position in Forte Biosciences in Q3 2021 and held it in 10 quarters.
Cutler Group's Forte Biosciences position peaked at $47K in Q3 2021.
32 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.